Editorial

What the FTC and NAD Have Flagged About Cardiovascular Supplements

Name: Daily Beets
Brand: Matter
Price: 19.99 GBP
Availability: InStock

A short editorial on the regulatory framework around heart-health supplement claims. The Cardio Miracle NAD ruling, the FTC’s Negative Option Rule, ASA enforcement in the UK, and what restrained claim language actually looks like.

NK Medically reviewed by Dr. Nouman Kazmi, MBBS FCPS ·11 min read

432/2012

EU permitted health claims regulation

FTC + NAD

US oversight bodies for ad claims

ASA

UK advertising regulator

“supports”

Permitted, not “treats”

Key Takeaways

Cardiovascular supplements operate inside a tightening regulatory perimeter. Multiple US bodies (FTC, NAD, FDA) and UK ones (ASA, MHRA, Trading Standards) have all weighed in on the kind of language permitted for heart-health products in recent years.
The National Advertising Division (NAD) case against Cardio Miracle, documented across legal commentary including BakerHostetler, set a recent reference point for the line between supportable and unsupportable nitric oxide supplement claims.
The FTC’s 2024 Negative Option Rule made subscription enrolment, automatic renewal and the “click to cancel” standard much more strictly enforced. Many supplement brands rely heavily on subscription revenue, which is why this matters.
In the UK, the ASA, MHRA and CAP Code govern advertising claims for food supplements. EU Regulation 432/2012 lists the specific health claim wordings that are permitted (the EU exit didn’t remove this; UK food law inherited and continues to apply it).
Restraint in advertising language correlates with restraint in formulation and stance. The brands operating in “supports” / “may help” territory tend to be the same ones disclosing ingredients precisely and pointing to the underlying evidence.

In This Article

Why supplement claims have become a regulatory focus
The Cardio Miracle case: what the NAD ruling said
The FTC Negative Option Rule and subscription supplements
The UK side: ASA, MHRA and the CAP Code
What restrained claim language actually looks like
Where Daily Beets fits
Frequently asked questions
The bottom line

Why supplement claims have become a regulatory focus

The wellness industry’s favourite phrase is “Big Pharma doesn’t want you to know this”. The regulators’ favourite phrase is “please cite the trial you’re relying on”. Over the past few years, those two phrases have collided more often. This piece is a short editorial on what’s been happening in cardiovascular supplement regulation, why it matters, and what a brand operating in this space ought to look like.

The cardiovascular supplement category is large, growing, and historically loose. Heart-health is a high-anxiety purchase: buyers tend to be older, more brand-trusting, and more willing to commit to a daily subscription. Claim inflation has followed the money. “Clinically proven to lower blood pressure” appears on packaging that has no business saying any such thing under UK or EU food-supplement law.

Three things have shifted recently:

Regulators have caught up. The US FTC, the NAD (a self-regulatory body that issues binding-ish recommendations on advertising claims), the UK ASA and the MHRA have all become more active in this space, with formal rulings against named brands appearing more regularly across legal trade press.
Subscription revenue has become a regulatory target. The FTC’s 2024 Negative Option Rule made it harder for brands to enrol customers into auto-renewing subscriptions without explicit consent, and harder to keep them in. Many supplement brands depend heavily on subscription revenue.
The legal trade press has caught up too. Sites like Lexology, BakerHostetler’s blog and Wiley.law’s alerts now publish detailed write-ups of every major NAD ruling, which has made the rulings easier for other brands (and journalists) to track.

None of this means heart-health supplements are inherently disreputable. It means the category is being asked to operate by clearer rules, which is mostly a good thing for buyers.

The Cardio Miracle case: what the NAD ruling said

Cardio Miracle is a US nitric oxide supplement that has been marketed with claims around blood pressure, circulation, energy and broader cardiovascular health. The case became a useful reference point because of how publicly the NAD reviewed it and how thoroughly the legal trade press covered the result.

The National Advertising Division of BBB National Programs is a US self-regulatory body. It reviews advertising claims (often initiated by competitor challenges or by self-monitoring) and issues recommendations on whether the claims are adequately supported. Companies can refuse to comply, in which case the matter is referred to the FTC. The system carries weight precisely because the FTC referral is the next step.

The Cardio Miracle review, summarised in legal commentary across BakerHostetler and other regulatory outlets, focused on a few categories of claim:

Specific clinical outcome claims tied to blood pressure that, in the NAD’s view, weren’t supported by trials on the specific product (as opposed to trials on individual ingredients).
Energy and performance claims that relied on the broader nitric oxide literature without product-specific evidence.
Health-effect claims that crossed into territory the NAD considered drug-like rather than dietary supplement-like.

The substantive lesson for the rest of the industry: trials on an individual ingredient do not, by themselves, support a claim about a specific finished product. A formula with 12 actives can’t cite a trial on one of those actives at a different dose, in a different population, and present it as evidence for what the finished product does. This is well-established in food law but routinely ignored in the marketing.

“Trials on individual ingredients do not, by themselves, support claims about specific finished products. This is well-established in food law but routinely ignored in the marketing.”

2024

The year the FTC finalised the Negative Option Rule (the “click to cancel” rule), tightening enforcement around subscription enrolment and automatic renewal. The supplement industry was one of the named target categories. Wiley.law’s alert summarises the obligations brands now carry around informed consent, easy cancellation, and pre-renewal notifications.

The FTC Negative Option Rule and subscription supplements

If you’ve ever tried to cancel a wellness subscription and ended up on the phone for twenty minutes with someone offering you a discount you didn’t ask for, you’ve experienced the situation the FTC’s Negative Option Rule was written to address.

The rule, finalised in 2024 and rolled out through 2025, applies to any business that enrols customers into auto-renewing subscriptions. The key provisions, summarised:

Informed consent at enrolment. The terms of the subscription (price, frequency, what happens at renewal) must be disclosed clearly and the customer must affirmatively agree.
Easy cancellation. If the customer enrolled online, the cancellation route must also be online and require no more steps than the enrolment did. The “click to cancel” framing comes from this.
Pre-renewal disclosure. For annual subscriptions, brands must remind customers ahead of renewal.
No misleading retention tactics. The customer service script that delays or discourages cancellation is now actively risky for the business running it.

The supplement industry was one of the named target categories in the FTC’s commentary. Many heart-health brands operate on subscription-default models (the “subscribe and save” tile being the cheapest single-purchase option, the auto-renewal being the actual revenue mechanism). The rule didn’t ban the model. It made the model honest about what it was.

For UK buyers ordering from US brands, this affects the experience indirectly. Brands that sell into the US must comply with FTC rules on their US site, and the operational changes tend to apply to their international checkout too. UK buyers benefit from cancellation flows being cleaner than they used to be.

Worth knowing

If you’re trialling a subscription supplement and want to know how serious the brand is about the rules, look at how their cancellation flow works. A clear “cancel my subscription” link in the account settings, with the cancellation taking effect before the next renewal, is a small but meaningful signal of operational restraint.

The UK side: ASA, MHRA and the CAP Code

The UK regulatory architecture for cardiovascular supplements is split across a few bodies, which is mildly confusing but not unreasonable once you map it.

ASA and the CAP Code

The Advertising Standards Authority is the UK’s independent advertising regulator. The Committee of Advertising Practice (CAP) writes the rules the ASA enforces. The relevant section for food supplements is Section 15 of the CAP Code, which deals with food, food supplements and associated health or nutrition claims. The ASA receives complaints (from competitors, consumers, and proactively), investigates, and publishes adjudications. UK supplement brands receive ASA rulings regularly.

In January 2026, the ASA expanded the rules around “less healthy food and drink” advertising to children, which made headlines. The cardiovascular supplement category sits alongside that change rather than inside it, but the broader signal was that the ASA was actively tightening the perimeter of permitted promotional content.

MHRA borderline products

The Medicines and Healthcare products Regulatory Agency draws the line between food supplement and medicine. If a product is presented (or formulated) as treating a disease, it crosses the line into medicines territory and requires a licence. Most cardiovascular supplements stay deliberately on the food-supplement side, which is why the language has to be restrained.

EU Regulation 432/2012

This is the list of permitted health claims for foods. It survived the UK’s departure from the EU as part of inherited food law and continues to apply in the UK. It specifies exact wordings for what each nutrient may claim. For example: “Vitamin B6 contributes to normal homocysteine metabolism”. The wording matters. Brands can use the permitted phrasing; they cannot rewrite it into something stronger.

The combined effect of these bodies is that UK supplement advertising has, on balance, less room to make large claims than US supplement advertising. Whether this is the right balance is its own debate. The practical reality is that UK brands operating honestly tend to use the more restrained language by default.

What restrained claim language actually looks like

Permitted phrasings, with their forbidden cousins:

“Supports normal blood pressure as part of a balanced diet.” Allowed. Notice the “normal” (rather than “high”) and “as part of a balanced diet” (rather than “regardless of your diet”).
Not allowed: “lowers blood pressure” / “treats hypertension” / “reduces high blood pressure”.
“Contributes to normal homocysteine metabolism.” Allowed verbatim for B6, folate and B12 under EU Regulation 432/2012.
Not allowed: “lowers homocysteine” / “reduces cardiovascular risk” / any disease-modification framing.
“Supports normal cardiovascular function.” Borderline; generally acceptable when tied to an ingredient with an EU-approved claim, and when the product is positioned as supplementary to a balanced diet.
Not allowed: “improves heart health” (too strong, implies measurable clinical change).
“Designed to support [outcome] as part of a balanced diet.” A common restrained construction. It signals support, ties it to the broader lifestyle context, and avoids the implication that the product alone is doing the work.
“May help [outcome].” Cautious framing. Useful when the evidence is real but limited or population-specific.

Three signals that a brand is operating restrainedly:

The ingredient list is fully disclosed at exact doses. Not “proprietary blend, 1,500mg” but each active named at its specific dose. Proprietary blends are a long-standing way to hide low doses of marquee ingredients.
The claim language sticks to the permitted EU phrasings. If you see “clinically proven to”, “guaranteed to” or “reverses” in the product copy, the brand is gambling that the regulator won’t notice.
The brand cites the evidence behind specific claims, not vague allusions to “research”. A real claim points to a specific trial, a specific dose, and a specific population.

The wellness industry’s favourite phrase is “clinically proven”. Ours is “here’s the study, page 14 is the bit that matters”.

Where Daily Beets fits

The honest disclosure: Matter is the brand publishing this article. Daily Beets is our product. So we have a position to declare, which is that operating inside the restrained-claim perimeter has been a deliberate choice rather than an accident.

Daily Beets uses the permitted EU phrasings (“supports normal cardiovascular function”, “contributes to normal homocysteine metabolism”), discloses each of the 12 active ingredients at exact doses on the label, and cites the specific evidence behind each ingredient rather than hand-waving at “research”. The 90-day money-back guarantee is on the product page in plain English with no fine-print maze, and the cancellation flow for subscription customers takes the same number of clicks as the subscribe flow did.

None of this is heroic. It’s how the category should already be operating. The reason it’s worth mentioning at all is that a meaningful share of cardiovascular supplements in this market still aren’t.

Daily Beets by Matter

Restrained claims. Specific evidence.

Concentrated beetroot, hibiscus, grape seed extract and a four-vitamin B complex, designed to support normal cardiovascular function as part of a balanced diet. All 12 ingredients disclosed at exact dose. UK brand, formulated in the UK.

Try the 90-Day Protocol → 12 active ingredients·Cardiologist-reviewed

Frequently asked questions

What is the NAD and why does it matter for supplements?

The National Advertising Division (NAD) is a US self-regulatory body within BBB National Programs. It reviews advertising claims (often initiated by competitor challenges) and issues recommendations on whether the claims are adequately supported by evidence. Companies can refuse to comply, in which case the matter is referred to the FTC. The system carries weight because the FTC referral is the consequence of non-compliance, and FTC investigations can result in substantial fines and consent decrees.

What is the FTC Negative Option Rule?

The FTC Negative Option Rule, finalised in 2024 and rolled out through 2025, governs how US businesses can enrol customers into auto-renewing subscriptions. The key obligations are informed consent at enrolment, an easy cancellation route (the “click to cancel” standard), pre-renewal disclosure for annual subscriptions, and no misleading retention tactics during cancellation. The supplement industry was one of the named target categories. Brands selling into the US, including international brands shipping to US customers, must comply.

What can UK supplement brands legally claim about blood pressure?

Permitted: “supports normal blood pressure as part of a balanced diet”. Not permitted: “lowers blood pressure”, “treats hypertension”, “reduces high blood pressure” or any phrasing that implies the product modifies a disease state. The wording is governed by the CAP Code, EU Regulation 432/2012 and ASA enforcement. The line is essentially between “supports a normal physiological state as part of a balanced diet” (food supplement) and “treats a disease” (medicine, requires MHRA licence).

How can I tell if a supplement brand is making compliant claims?

Three signals to look for. First, the ingredient list is fully disclosed at exact doses (no “proprietary blend”). Second, the claim language uses permitted phrasings (“supports” / “may help” / “contributes to normal”) rather than disease-modification language (“lowers” / “treats” / “reverses”). Third, specific evidence is cited (named trial, named dose, named population) rather than vague allusions to research. If a brand fails all three, the regulator may not have caught up yet but the claims are unlikely to be reliable.

Are supplement subscriptions worth using?

The format can suit people who are committing to a 90-day window and want the price break that a subscription typically offers. The key practical question is the cancellation flow. A brand with a one-click cancel option in the account settings is operating transparently; a brand that requires a phone call or hides the cancellation under multiple layers is using friction to retain customers. Post-FTC Negative Option Rule, this has become a meaningful signal of how seriously the brand takes its obligations.

Why don’t supplements claim to “lower” blood pressure if the evidence supports it?

Because “lowering blood pressure” is a medical claim that, under UK and EU food law, would make the product a medicine rather than a food supplement. Medicines require an MHRA licence, clinical trials at scale, and a substantially different regulatory framework. A food supplement that “supports normal blood pressure as part of a balanced diet” sits inside a different regulatory category and is the one supplement brands are required to operate in. The restraint isn’t modesty; it’s the law.

The bottom line

The cardiovascular supplement category is operating in a tightening regulatory perimeter, and that’s mostly good news for buyers. The FTC and NAD in the US, the ASA and MHRA in the UK, and EU Regulation 432/2012 across both jurisdictions have set out what supplement claims can look like. The brands that comply use restrained language because that’s what the law permits. The brands that don’t are gambling that the regulator won’t catch up before the next funding round.

When you’re evaluating a heart-health supplement, the three signals worth checking are: full ingredient disclosure at exact doses, permitted claim language, and specific evidence cited per ingredient. None of those guarantee the product will work for you. All of them indicate the brand is taking the rules seriously, which correlates with taking the formulation seriously.

Boring. Legal. Correct. Three words that don’t sell as well as “clinically proven”, but tend to age better.

Continue Learning

References

BBB National Programs / National Advertising Division. Cardio Miracle case write-up and recommendations. Available via NAD case archive.
BakerHostetler. Advertising law alerts and NAD case commentary (Cardio Miracle and similar cardiovascular supplement reviews). Available at: bakerlaw.com
Lexology. Regulatory write-ups on NAD enforcement in the supplements sector. Available at: lexology.com
Wiley Rein LLP. FTC Negative Option Rule alert (2024). Available at: wiley.law
Federal Trade Commission. Negative Option Rule final text. Available at: ftc.gov
Advertising Standards Authority. UK Code of Non-broadcast Advertising and Direct & Promotional Marketing (CAP Code), Section 15 Food, food supplements and associated health or nutrition claims. Available at: asa.org.uk
ASA News. Coverage of the January 2026 less-healthy-food advertising rule expansion. Available at: asa.org.uk
European Commission. Regulation (EU) No 432/2012 establishing a list of permitted health claims made on foods. Available at: eur-lex.europa.eu
MHRA. Borderline products: guidance on the boundary between medicines and food supplements. Available at: gov.uk/mhra

Back to the Heart Health Resource Centre